



Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16

November 10, 2020

Management to host a conference call and webcast at 4:30 PM ET on that day

IRVINE, Calif.--(BUSINESS WIRE)--Nov. 10, 2020-- Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.

Conference Call Details

Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time

Toll Free: 877-407-3982

International: 201-493-6780

Conference ID: 13713171

Webcast: <http://public.viavid.com/index.php?id=142451>

About Novus Therapeutics

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company's website at www.novustherapeutics.com.

Follow Novus Therapeutics on social media: [@Novus_Thera](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201110006234/en/): <https://www.businesswire.com/news/home/20201110006234/en/>

Media

Amanda Sellers

asellers@vergescientific.com

301-332-5574

Investors

Bruce Mackle

LifeSci Advisors. LLC

bmackle@lifesciadvisors.com

929-469-3859

Source: Novus Therapeutics, Inc.